Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956939 · ClinicalTrials.gov registry record
Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 38
- Enrollment target
NCT04956939: Completed study, sponsored by Rush University Medical Center.
NCT04956939 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04956939 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
Levodopa (LD) is an effective treatment to control symptoms of Parkinson's disease (PD). However, the response to (the effectiveness) LD changes over time and patients require higher and more frequent LD doses for treatment. The purpose of this study is to identify what reasons or causes might influence the changes in LD effectiveness, particularly if intestinal bacteria contribute to the breakdown of LD in patients with PD. This study is an observational cohort proof-of-concept study that follows PD patients who take PD at high-frequency doses and low-frequency doses. . Each PD patient will have a household healthy control/spouse enrolled into the study. Single patients with no spouse will still be eligible to enroll.
Primary Outcome
Quantitative polymerase chain reaction (qPCR), 16S rRNA Sequencing and Shotgun Metagenomics
Interventions
- DRUG Low dose levodopa
- DRUG High dose levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2021-03-31 |
What the finished NCT04956939 record still lists
NCT04956939 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Low dose levodopa is the first listed.
NCT04956939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04956939 about?
NCT04956939 is a clinical study titled "Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease". Levodopa (LD) is an effective treatment to control symptoms of Parkinson's disease (PD). However, the response to (the effectiveness) LD changes over time and patients require higher and more frequent LD doses for treatment. The purpose of this study is to identify what reasons or causes might influ...
What is the current status of trial NCT04956939?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2018-07-17. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT04956939?
The interventions under investigation include: Low dose levodopa (DRUG), High dose levodopa (DRUG).
Who is sponsoring clinical trial NCT04956939?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI